Coletta Alison P, Clark Andrew L, Seymour Anne Marie L, Cleland John G F
Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, HU15 5JQ, Kingston-upon-Hull, UK.
Eur J Heart Fail. 2003 Aug;5(4):545-8. doi: 10.1016/s1388-9842(03)00111-9.
This article continues a series of reports on recent research developments in the field of heart failure. Key presentations made at the European Society of Cardiology Heart Failure Update meeting, held in Strasbourg, France are described. The COMET study showed a 17% relative risk reduction in all-cause mortality with carvedilol compared with metoprolol tartrate. The COMPANION study, as previously reported, showed encouraging results for the use of cardiac resynchronisation and implantable defibrillator therapy in patients with heart failure, but further evidence is awaited. The results of a study on tezosentan suggest that lower doses of this endothelin antagonist may be clinically more effective with fewer adverse effects compared with higher doses. The SHAPE survey of heart failure awareness in Europe identified a need for further heart failure education amongst the public, patients, their carers and primary care physicians.
本文延续了关于心力衰竭领域近期研究进展的一系列报道。文中描述了在法国斯特拉斯堡举行的欧洲心脏病学会心力衰竭最新进展会议上的重要发言。COMET研究表明，与酒石酸美托洛尔相比，卡维地洛可使全因死亡率相对降低17%。如先前报道，COMPANION研究显示，心脏再同步化治疗和植入式心脏除颤器治疗在心力衰竭患者中的应用取得了令人鼓舞的结果，但仍有待进一步的证据。一项关于替唑生坦的研究结果表明，与高剂量相比，较低剂量的这种内皮素拮抗剂可能在临床上更有效，且不良反应更少。欧洲心力衰竭认知度SHAPE调查表明，公众、患者、其护理人员和初级保健医生都需要进一步接受心力衰竭教育。
